Significance of TIMP-1 and nm-23 expressions in HER-2-positive breast cancer / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 600-604, 2012.
Article
in Chinese
| WPRIM
| ID: wpr-307334
ABSTRACT
<p><b>OBJECTIVE</b>Trastuzmab combined therapy has been recommended as standard therapy for HER-2-positive breast cancer. However, more than 70% HER-2-positive cases do not recur and might thus be with overtreatment risk. The aim of this study was to explore the significance of TIMP-1 and nm-23 expression in identifying the good prognosis subtype in HER-2-positive breast cancer.</p><p><b>METHODS</b>One hundred and sixty-five cases of HER-2-positive breast cancer treated in Tianjin Medical University Cancer Hospital from Jan. 1987 to Dec. 1988 were studied. Expressions of TIMP-1 and nm-23 were detected by immunohistochemistry and the correlation with clinicopathologic characteristics and long-term outcome was analyzed.</p><p><b>RESULTS</b>53.3% (88/165) of TIMP-1 and 72.7% (120/165) of nm-23 expression were detected in the patients. The TIMP-1-negative patients classified as good prognosis group had a 10-year metastasis free survival (MFS) of 58.4% and 10-year overall survival (OS) of 68.8%, compared with the 10-year MFS of 43.2% (P = 0.041) and 10-year OS of 52.0% in the positive group (P = 0.020). The nm-23-positive patients classified as good prognosis group had a 10-year MFS of 54.2% and 10-year OS of 65.7%, compared with the 10-year MFS of 40.0% (P = 0.049) and 44.1% (P = 0.015) in the negative group. The multivariate analysis showed that expressions of TIMP-1 and nm-23, tumor size and lymph node involvement were independent prognostic factors.</p><p><b>CONCLUSIONS</b>In HER-2-positive breast cancer, TIMP-1 and nm-23 can be used to further distinguish between low-risk and high-risk subgroups, and they are independent factors in prognosis.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
General Surgery
/
Breast Neoplasms
/
Mastectomy, Modified Radical
/
Survival Rate
/
Carcinoma, Ductal, Breast
/
Receptor, ErbB-2
/
Disease-Free Survival
/
Tissue Inhibitor of Metalloproteinase-1
/
Tumor Burden
Type of study:
Prognostic study
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
Language:
Chinese
Journal:
Chinese Journal of Oncology
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS